Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

    SBC: Zymeron Corporation            Topic: CBD181004

    Given the unforeseen/unanticipated use of nerve agents in the battlefield and on the homeland, military personnel can benefit from this oncedaily pretreatment. It may also be desirable to pretreat certain medical and emergency aid personnel following a known/suspected nerveagent attack. Also, a novel, improved PB extended release formulations can be commercialized for the treatment of myasthenia g ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. Microcapillary Quartz Sensors for Screening Injectability of High Concentration Protein Formulations

    SBC: Qatch Technologies, LLC            Topic: None

    The objective of this SBIR Phase I proposal is to determine the feasibility of viscosity characterization of high concentration protein formulations (HCF) by QATCH’s microcapillary quartz technology. HCFs are non-Newtonian fluids with shear-thinning behavior and they are administered to patients by subcutaneous or muscular injections. The injectability of HCFs depends on the viscosity at high-sh ...

    SBIR Phase I 2019 Department of CommerceNational Institute of Standards and Technology
  3. Rapid Point-of-Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood

    SBC: Zymeron Corporation            Topic: NIAID

    TuberculosisTBis currently the leading infectious cause of death worldwideTB treatment includes multiple different combinations of antibioticsdosesand long time periodsThe current standard includes an intensive phase ofmonthsfollowed by a continuation phase of eitherormonthsHowevertreatment outcome can be poor due to drug drug interactionsimpaired medication adherencedrug absorption and metabolism ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Targeted Degradation of HIV Gag Polyprotein by Gag-PROTAC Reagents

    SBC: Zymeron Corporation            Topic: NIAID

    HIV disease continues to be a serious health issue for the whole worldCurrentlyantiretroviral therapyARTis a widely accepted treatment to HIV infected patientswhich reduces morbidity and mortality and the potential for HIV transmission by suppressing viral replicationHowevertreatment outcomes of ART are limited due to the high adherence requirement and occurrence of drug resistanceProteolysis targ ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. SBIR PHASE 1- TOPIC 394- COMBINATORY TREATMENT MODALITIES UTILIZING RADIATION TO LOCALLY ACTIVATE OR RELEASE SYSTEMICALLY DELIVERED THERAPEUTICS.

    SBC: Zymeron Corporation            Topic: NCI

    Photodynamic therapyPDTutilizes light beam to activate photosensitizers to produce cytotoxic reactive oxygen speciesROSand it has been proposed as a potent treatment to combine with Radiation TherapyRTespecially for the idea of using X ray beam to locally activate PDTXPDTMajority studies about XPDT have used nanoscintillators as the X ray transducer to activate photosensitizersHoweverthe materials ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 382- INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW

    SBC: Cell Microsystems, Inc.            Topic: NCI

    Combining both genomic analysis and highEresolution imaging on a cellEbyEcell basis typically relies on customized technology which often requires significant expertise and capital costCell MicrosystemsInchas partnered with Peter SimsPhD of Columbia University to commercialize a novel workflow for integrated imaging and sample preparation for single cell transcriptomic analysisDrSims workflowSingl ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. An integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings.

    SBC: CERTIRX CORPORATION            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop an integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a fixed-dose combination therapy for the treatment of chronic musculoskeletal pain

    SBC: NeuroCycle Therapeutics, Inc.            Topic: NIAMS

    PROJECT SUMMARY Non steroidal anti inflammatory drugsNSAIDsare a first line pharmacologic pain therapy for chronic musculoskeletal painand rheumatoid arthritisRAand moderate to severe osteoarthritisOAspecificallyHoweverinsufficient pain relief by NSAID monotherapy has encouraged the use of combination therapyCombinations of NSAIDs plus weak opioids are widely used although objective evidence for e ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding

    SBC: Dignify Therapeutics LLC            Topic: 105

    PROJECT SUMMARYABSTRACTSpinal cord injurySCIaffects an estimatedAmericansDamage to nerves in the spinal cord can result in a loss of voluntary control over bladder and bowel function that often produces both incontinence and retention of urine and stools in the same patientThe standard of care for urine retention is bladder catheterization to void urinewhich may produce urinary tract infectionsUTI ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain

    SBC: AFFINERGY, LLC            Topic: NIDA

    SUMMARY ABSTRACT Chronicnon cancer pain is a significant unmet health need worldwideThe prevalence of chronic pain among adults in the United States has been estimated at betweenandThe personal toll of living with chronic pain is immenseand the economic impact can be devastatingOne of the most widely used treatments for chronic pain is opioid analgesicsWhile the appropriate use of opioids can be a ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government